Collaboration provides a convenient, fast tool for multiplexed immunofluorescence imaging in translational studies WALTHAM and CAMBRIDGE, Mass., (Nov. 7, 2022)—Evident Corporation, a premier manufacturer of life science imaging systems, and Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas. Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW™ VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organizations in the Americas. The collaboration builds on their existing partnership to meet the scientific community’s increasing need for fluorescent multiplexing. Ultivue develops unique solutions for mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal-to-noise data is designed for fast and comprehensive exploration of up to 12 biologically relevant targets in one tissue slide, with same-slide hematoxylin and eosin (H) analysis in tissue samples. This technology combines the power of computational pathology and spatial biology to guide translational science in immuno-oncology. Evident Corporation, a wholly owned subsidiary of Olympus Corporation, manufacturers leading-edge life science microscopes that support a broad range of academic and clinical research areas, pathology diagnostic services and the growing demand for novel drug discovery. The Olympus VS200 slide scanner has advanced the field of whole slide imaging with high-quality optics, fast scanning and flexible imaging options that include a robust solution for fluorescent multiplexing. “We are excited to enhance our relationship with Evident to further optimize the integration of Ultivue assays on the SLIDEVIEW VS200 research slide scanner. We jointly enable highly efficient workflows to drive adoption of tissue multiplexing on larger cohorts,” said Florian Leiss, PhD, the Vice President of Product Strategy and Corporate Development at Ultivue. “We are delighted to continue to collaborate with Ultivue to provide a total solution for multiplexing,” said Lee Wagstaff, the Vice President of Life Science Sales and Marketing at Evident Americas. “With Ultivue’s assays and our slide scanning technology, we can provide a complete workflow solution for our customers that enables them to work more efficiently.” About EVIDENTAt Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work, whether it is researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products. Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF, and other clinical applications as well as for research and education. For more information, EvidentScientific.com. About UltivueUltivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com. Media Contact: Evident and the Evident logo are trademarks of Evident Corporation or its subsidiaries. |
Not available in your country.
Sorry, this page is not available in your country